Title : DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.

Pub. Date : 2020 Jul 16

PMID : 32677976






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Furthermore, DT2216 combined with ABT199 (a selective Bcl-2 inhibitor) synergistically reduced disease burden and improved survival in a TCL PDX mouse model dependent on both Bcl-2 and Bcl-xL. venetoclax B cell leukemia/lymphoma 2 Mus musculus
2 Furthermore, DT2216 combined with ABT199 (a selective Bcl-2 inhibitor) synergistically reduced disease burden and improved survival in a TCL PDX mouse model dependent on both Bcl-2 and Bcl-xL. venetoclax B cell leukemia/lymphoma 2 Mus musculus